Arterial thromboembolic events.

[pjoshea13]

New study below.

"... we identified 374,331 patients ≥67 years of age with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005-2013. Cancer patients were individually matched by demographics and comorbidities to Medicare beneficiaries without cancer ..."

"... the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before."

We know that cancer is associated with abnormal coagulation, & over the years, there have been recommendations that older men presenting with DVTs, etc, be screened for PCa. But the new study is interesting, in verifying that dysfunctional coagulation is an early event for cancer in general.

So, when one receives a PCa diagnosis, why are we not warned? Why are we not monitored? According to my doctor, it's because there is no safe response to increased risk. One must first end up in the ER to qualify for an anticoagulation drug. They are too dangerous to use as prophylactics.

I have numerous old posts on the subject. Having once found myself in the ER with a double DVT, & been punished with 3 months of Warfarin (& zero vitamin K), I was relieved to find a solution:

A] A D-dimer blood test result of near zero means no blood clot.

B] Nattokinase will speed the breakdown of unwanted clots.

Nattokinase can also be used as a prophylactic. The appropriate nattokinase dose in either case can only be determined by D-dimer monitoring.

-Patrick

ncbi.nlm.nih.gov/pubmed/305...

Blood. 2018 Dec 21. pii: blood-2018-06-860874. doi: 10.1182/blood-2018-06-860874. [Epub ahead of print]

Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Navi BB1, Reiner AS2, Kamel H3, Iadecola C2, Okin PM4, Tagawa ST5, Panageas KS6, DeAngelis LM7.

Author information

1

Department of Neurology, Weill Cornell Medicine, New York, NY, United States; [e-mail].

2

Department of Neurology, Weill Cornell Medicine, New York, NY, United States.

3

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States.

4

Department of Medicine, Division of Cardiology, Weill Cornell Medicine, New York, NY, United States.

5

Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States.

6

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

7

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Abstract

Cancer patients face an increased risk of arterial thromboembolism; however, it's uncertain when this excess risk begins. This study evaluated the risk of arterial thromboembolism before cancer diagnosis. Using the population-based Surveillance Epidemiology and End Results-Medicare linked dataset, we identified 374,331 patients ≥67 years of age with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005-2013. Cancer patients were individually matched by demographics and comorbidities to Medicare beneficiaries without cancer, who served as controls. Validated diagnosis codes were used to identify arterial thromboembolic events, defined as a composite of myocardial infarction or ischemic stroke. The Mantel-Haenszel estimator was used to compare risks of arterial thromboembolic events between cancer and non-cancer groups during 30-day periods in the 360 days before date of cancer diagnosis. From 360 to 151 days before cancer diagnosis, the 30-day interval risks of arterial thromboembolic events were similar between cancer patients and matched controls. From 150 to 1 day before cancer diagnosis, the interval 30-day risks of arterial thromboembolic events were higher in cancer patients versus matched controls, progressively increasing as the cancer diagnosis date approached, and peaking during the 30-days immediately before cancer diagnosis, when 2,313 (0.62%) cancer patients were diagnosed with an arterial thromboembolic event versus 413 (0.11%) controls (odds ratio, 5.63; 95% confidence interval, 5.07-6.25). In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before.

PMID: 30578253 DOI: 10.1182/blood-2018-06-860874

[cesanon]

Hmmm

Fish oil and vitamin k and baby aspirin might be able to help out a bit in the anti coagulant department.

Not like a real anti-coagulant, but a little?

[Hidden]

So prior to a biopsy or surgery nattokinase, like nsaids, should be discontinued for a week too?

[pjoshea13 in reply to Hidden]

I don't know how quickly the enzyme is cleared, but a week seems prudent.

-Patrick

[Advo__cate]

Do you know of people or any info who remain on Natto while also on Plavix and aspirin?

[pjoshea13 in reply to Advo__cate]

Plavix and aspirin are anti-platelet, whereas nattokinase is anti-fibrin. There should be no conflict. But taking both types of inhibitor, while that appeals to my belt-&-suspenders instincts, is overkill. I haven't heard of anyone doing both.

But this could happen, I suppose, in men who are not monitoring D-dimer. It's wishful thinking to expect a low-dose aspirin & 2,000 FUs of nattokinase to be protective in the altered coagulation world of PCa.

-Patrick

[Escudilla]

Great info Patrick! I appreciate all the posting you've done on this (and other) subjects. My D-dimer wants some Natto!